IT'S OIL THE SAME TO US
New human health trial shows plant produced omega-3 fats are just as effective nutritionally as fish oil.
Research, led by the University of Southampton’s Faculty of Medicine, has shown that key omega-3 fatty acids within GM plant oils are taken up and processed by the body in exactly the same way as when fish oils are eaten.
The findings are great news for Rothamsted, where Prof Johnathan Napier has pioneered the modification of the Camelina plants to produce the enhanced vegetable oil in their seeds.
He said: “It is genuinely exciting to see our research progress to the point where we are carrying out human studies, and even more pleasing to see such positive results.
"This first study in humans is both an important scientific advance and another step on our journey towards making this oil available to the consumer."
Mainly found in fish oil and oily fish, the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are key components of cell membranes and important for health and development, but there are no natural plant sources of these omega-3s.
The fats are well known to help protect against heart disease and strokes, but the UK population consumes less than half the recommended amounts of these key nutrients, mainly due to dietary choices that exclude fish, such as vegetarianism.
Additionally, current marine supplies can only meet 15 per cent of global demand, so there is a need for a source of omega-3 oils that is broadly acceptable to consumers, which can be scaled up to meet demands, and is sustainable.
Researchers at the University, led by Professor Graham Burdge, have for the first time tested in people whether the oil from the genetically modified plant is as good as fish oil in providing these fatty acids.
Their findings, which are published in the British Journal of Nutrition, show that when young and middle-aged men and women consumed the same amount of key fatty acids in a single standard meal, either as fish oil or as the oil from the genetically modified plant, there was no difference in their uptake or in the processing of the fats by the body.
Moreover, there was no difference between men and women, but older participants appeared to take up they fatty acids more efficiently. Significantly, there were no adverse effects on those who had consumed the modified oil.
Professor Graham Burdge, University of Southampton said: “These findings show that the oil from this transgenic plant is an effective and apparently safe means of providing EPA and DHA in the diet which overcomes the negative effect on EPA and DHA intakes of consuming a diet that excludes animal products.
“Furthermore, subject to further testing and regulatory approval, this would represent a unique opportunity for farmers that could have a positive impact on the nutrition of the global population.”
For more information on Rothamsted's work on Camelina, go to the impact story, “From oceans to fields and back again”.
About Rothamsted Research
Rothamsted Research is the longest-running agricultural research institute in the world. We work from gene to field with a proud history of ground-breaking discoveries, from crop treatment to crop protection, from statistical interpretation to soils management. Our founders, in 1843, were the pioneers of modern agriculture, and we are known for our imaginative science and our collaborative influence on fresh thinking and farming practices.
Through independent science and innovation, we make significant contributions to improving agri-food systems in the UK and internationally. In terms of the institute’s economic contribution, the cumulative impact of our work in the UK was calculated to exceed £3000 million a year in 20151. Our strength lies in our systems approach, which combines science and strategic research, interdisciplinary teams and partnerships.
Rothamsted is also home to three unique resources. These National Capabilities are open to researchers from all over the world: The Long-Term Experiments, Rothamsted Insect Survey and the North Wyke Farm Platform.
We are strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), with additional support from other national and international funding streams, and from industry. We are also supported by the Lawes Agricultural Trust (LAT).
For more information, visit https://www.rothamsted.ac.uk/; Twitter @Rothamsted
1Rothamsted Research and the Value of Excellence: A synthesis of the available evidence, by Séan Rickard (Oct 2015)
The Biotechnology and Biological Sciences Research Council is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government.
BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by government, BBSRC invested £469 million in world-class bioscience in 2016-17. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
More information about BBSRC, our science and our impact.
More information about BBSRC strategically funded institutes
The Lawes Agricultural Trust, established in 1889 by Sir John Bennet Lawes, supports Rothamsted Research’s national and international agricultural science through the provision of land, facilities and funding. LAT, a charitable trust, owns the estates at Harpenden and Broom's Barn, including many of the buildings used by Rothamsted Research. LAT provides an annual research grant to the Director, accommodation for nearly 200 people, and support for fellowships for young scientists from developing countries. LAT also makes capital grants to help modernise facilities at Rothamsted, or invests in new buildings.